IDT Biologika GmbH, the leading European auxiliary of SK Bioscience, has sailed on a full-scale ocean to extend its contract development and manufacturing (CDMO) business in biopharmaceuticals and vaccines. Last month and the start of November, the IDT took part in three of the company’s global events.
Events such as CPHI (Convention on Pharmaceutical Ingredients), the Frankfurt 2025 in Germany, the ongoing BIO-Europe 2025 in Vienna and World Vaccine Congress Europe 2025 (WVC) in Amsterdam witnessed IDT’s robust end-to-end manufacturing solutions and collaborative strategies, covering from early development to complete commercial production.
The world’s largest vaccine conferences, WVC 2025, are capturing R&D via commercialisation. IDT is called out for its collaborative meetings with research institutes and pharmaceutical companies globally. This spotlighted the company’s unified potential in microbial-based and cell culture operations, quality validation, fill-finish operations and process development. Apart from this, the IDT shared its well-established, trimmed in-house assay for reliable sizing and highly precise sensitivity quantification of DNA, the host cell.
The IDT’s theme ‘Connecting Innovation from Research to Commercial Manufacture’ complements this year’s congress theme. Under this, the company underscores its scalable CDMO platform, contributing next-generation modalities like immune therapeutics, monoclonal antibodies and gene therapy, along with vaccines.
In CPHI 2025’s event’s theme ‘Trusted Manufacturing Expertise with a Strong Partnership Commitment’, IDT emphasises its reliable supply chains, long-standing experience with global regulatory and European frameworks and flexible production infrastructure. This strengthened IDT’s position as a trusted, valuable CDMO partner for clients globally.
At Europe’s largest biopharmaceutical partnering conference, BIO-Europe 2025, IDT sharply focused on its drug-product and drug-substance manufacturing solutions mainly for sterile injectables. At this meeting company ramped up its aseptic production technologies, modern process know-how and unified best CDMO services, contributing to the development via a commercialisation move while indulging in collaborative discussion with all clients.
With these two events, including one ongoing, the IDT have built a powerful roof and wall to its role as a smart manufacturing partner offering trimmed end-to-end solutions, shifting from traditional contract production. By accelerating its partnership with SK Bioscience, the company is leveraging its initiatives to extend project acquisitions and global partnerships.
The Co-CEO of IDT Biologika, Dr Sally Choe, showed gratefulness to these events that gave chance to IDT to elaborate its partnership potential and manufacturing excellence at the larger platform.
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
